Articles From: Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia to AMN Healthcare Promotes Jeanette Sanchez to Chief Information Officer


Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif.
Sign-up for Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia investment picks
NEW YORK (MarketWatch) -- Amgen Inc. shares (AMGN) climbed 3.5% in premarket trade Monday, after the company said a late-stage trial of a treatment for patients with relapsed multiple myeloma had positive results.
Sign-up for Amgen reports positive trial of multiple myeloma treatment investment picks
2014/8/4
By Joshua Jamerson Amgen Inc. said its Kyprolis drug met its primary endpoint in an interim analysis, showing progression-free survival for patients treated with relapsed multiple myeloma.
Sign-up for Amgen reports successful late-stage trial of cancer treatment investment picks
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA investment picks
Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency investment picks
First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Morgan Stanley Global Healthcare Conference investment picks
Second Quarter 2014 GAAP EPS Were $2.01 2014 Total Revenues and Adjusted EPS Guidance Increased to $19.5-$19.7 Billion and $8.20-$8.40, Respectively Reallocating Resources to Drive Growth THOUSAND OAKS, Calif.
Sign-up for Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 investment picks
GREENVILLE, S.C., Sept.
Sign-up for AMIC Chicago Implements eRAD PACS Cloud Solution investment picks
2014/8/18
Amica Mature Lifestyles Inc. (“Amica” or the “Company”) (TSX Symbol:ACC) is pleased to announce the Company’s operating and financial results for the fiscal year and fourth quarter ended May 31, 2014.
Sign-up for Amica Mature Lifestyles Announces Fourth Quarter and Year End Results for Fiscal 2014 and Quarterly Dividend investment picks
2014/7/9
Amica Mature Lifestyles Inc. (“Amica” or the “Company”) announced today that it will be releasing its fourth quarter and year end results on Monday, August 18, 2014, before the market opens.
Sign-up for Amica Mature Lifestyles to Announce Fourth Quarter and Year End Results and Host Conference Call on August 18, 2014 investment picks
By Michael Calia Amicus Therapeutics said Wednesday that a potential treatment for Fabry disease reached its primary endpoints in a late stage study.
Sign-up for Amicus Therapeutic's Fabry treatment meets goals in late-stage trial investment picks
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function CRANBURY, N.J., Aug.
Sign-up for Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012 investment picks
Results From Second Phase 3 Fabry Monotherapy Study (Study 012) on Track for 3Q14 CRANBURY, N.J., Aug.
Sign-up for Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates investment picks
Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14 96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension Statistical Analysis Plan Finalized CRANBURY, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today provided updates and detailed the statistical analysis plan for its second Phase 3 study ( Study 012 ) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations.
Sign-up for Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012 investment picks
CRANBURY, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, August 7, 2014 at 5:00 p.m. ET to discuss financial results for the second quarter ended June 30, 2014.
Sign-up for Amicus Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014 investment picks
2014/9/9
By Kevin Clark As the National Football League faced widening criticism Tuesday over its handling of the Ray Rice domestic-violence episode, top people inside the league appeared to be standing by its commissioner.
Sign-up for Amid Criticism Over Ray Rice, NFL Owners Back Roger Goodell investment picks
Amira Nature Foods Ltd (the “Company”) (NYSE: ANFI), a leading global provider of branded packaged Indian specialty rice, today announced the launch of Amira branded products in Ratnadeep supermarkets in Hyderabad and Secunderabad, India.
Sign-up for Amira Expands Distribution in India with Launch of Amira Branded Products at Ratnadeep Supermarkets investment picks
2014/8/21
Amira Nature Foods Ltd (the “Company”; NYSE: ANFI), a leading global provider of branded and packaged Indian specialty rice, announced today that it will release its first quarter 2015 financial results on Thursday, August 28, 2014, at 4:30 p.m. ET.
Sign-up for Amira Nature Foods Ltd Announces First Quarter 2015 Earnings Release Date and Conference Call investment picks
2014/8/28
Amira Nature Foods Ltd (the “Company;” or “Amira” NYSE: ANFI), a leading global provider of packaged Indian specialty rice, today reported financial results for its fiscal 2015 first quarter which ended on June 30, 2014.
Sign-up for Amira Nature Foods Ltd Announces First Quarter 2015 Financial Results investment picks
2014/8/11
Amira Nature Foods Ltd (the “Company;” NYSE:ANFI), a leading global provider of branded and packaged Indian specialty rice, announced today that it has engaged FTI Consulting’s Strategic Communications practice (“FTI Consulting”) to develop and implement a comprehensive investor and media relations program for the Company.
Sign-up for Amira Nature Foods Ltd Retains FTI Consulting as Investor and Media Relations Counsel investment picks
Amira Nature Foods Ltd (the "Company") (NYSE: ANFI), a leading global provider of branded packaged Indian specialty rice, today announced management will present at the Oppenheimer 14 th Annual Consumer Conference on June 25, 2014 at 2:25 p.m. ET.
Sign-up for Amira Nature Foods Ltd to Participate in the Oppenheimer 14th Annual Consumer Conference investment picks
BETHESDA, Md., June 17, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) , a global biopharmaceutical company, today announced that the United Kingdom's (U.K.) National Institute of Health and Care Excellence (NICE) has released a Final Appraisal Determination with guidance for the recommendation of the use of AMITIZA ® (lubiprostone) in the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults who have failed laxatives.
Sign-up for AMITIZA(R) (Lubiprostone) Receives NICE Recommendation investment picks
Amkor Technology, Inc. (NASDAQ: AMKR) today announced that David Watson has been appointed as a new member of the Company’s Board of Directors.
Sign-up for Amkor Technology Names David Watson to Board of Directors investment picks
Amkor Technology, Inc. (NASDAQ:AMKR), a leading provider of semiconductor packaging and test services, today announced financial results for the second quarter ended June 30, 2014, with net sales of $767 million, net income of $50 million, and earnings per diluted share of $0.21. Net income includes a net gain of $18 million ($0.08 per diluted share) related to the sale of Amkor's Japanese subsidiary to J-Devices, Amkor's 60% owned joint venture in Japan.
Sign-up for Amkor Technology Reports Financial Results for the Second Quarter 2014 investment picks
Quarterly revenue of $251 million above the high end of guidance, adjusted EPS of $0.19 SAN DIEGO , July 31, 2014 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AHS) , healthcare's innovator in workforce solutions and staffing services, today announced second quarter 2014 financial results exceeded the Company's guidance for revenue and adjusted EBITDA.
Sign-up for AMN Healthcare Announces Second Quarter 2014 Results investment picks
Susan Salka Recognized for Corporate Citizenship SAN DIEGO , July 30, 2014 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AHS) , the innovator in healthcare workforce solutions and largest provider of staffing services in the nation, announced today that Susan Salka , AMN's President, CEO and Director, has been named Director of the Year for Corporate Citizenship by the Corporate Director's Forum.
Sign-up for AMN Healthcare CEO Named Director of the Year investment picks
Newly developed role will focus on consulting with clients to identify emerging workforce needs SAN DIEGO , Aug.
Sign-up for AMN Healthcare Hires Dr. Brenda Fischer to Vice President of Education and Professional Advancement investment picks
Leader of multi-year project to revolutionize company's business systems SAN DIEGO , July 22, 2014 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AHS) , the innovator in healthcare workforce solutions and largest provider of staffing services in the nation, has announced the promotion of Jeanette Sanchez to the role of Chief Information Officer.
Sign-up for AMN Healthcare Promotes Jeanette Sanchez to Chief Information Officer investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia to AMN Healthcare Promotes Jeanette Sanchez to Chief Information Officer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices